5:19 PM
 | 
Apr 22, 2010
 |  BC Extra  |  Clinical News

Pyramax meets malaria endpoint

Data from a Phase III trial to treat malaria showed that once-daily oral Pyramax pyronaridine-artesunate from Shin Poong Pharmaceutical Co. Ltd. (KSE:019170) and Medicines for...

Read the full 112 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >